熱門資訊> 正文
维拉克塔计划探索战略选择
2024-12-27 22:04
- Cancer drug developer Viracta Therapeutics (NASDAQ:VIRX) traded ~15% lower in the premarket on Friday after announcing plans to explore strategic alternatives, including a sale or a merger deal, to maximize shareholder value.
- Concurrently, the company announced it would close its pivotal Phase 2 clinical trial for its lead candidate, Nana-val, in relapsed or refractory (R/R) Epstein-Barr virus-positive (EBV+) lymphoma.
- The Cardiff, California-based biotech stressed that its decision to close the NAVAL-1 trial reflected its aim to extend cash runway and was unrelated to any new safety finding. Meanwhile, its discussions on strategic alternatives have already started.
- “I continue to believe that Nana-val has the potential to improve the treatment of relapsed/refractory EBV+ lymphomas, and I remain hopeful that it will one day be approved,” CEO Mark Rothera added.
More on Viracta Therapeutics
- Seeking Alpha’s Quant Rating on Viracta Therapeutics
- Historical earnings data for Viracta Therapeutics
- Financial information for Viracta Therapeutics
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
